WO2001016300A3 - Method of identifying inhibitors of cdc25 - Google Patents

Method of identifying inhibitors of cdc25 Download PDF

Info

Publication number
WO2001016300A3
WO2001016300A3 PCT/US2000/023473 US0023473W WO0116300A3 WO 2001016300 A3 WO2001016300 A3 WO 2001016300A3 US 0023473 W US0023473 W US 0023473W WO 0116300 A3 WO0116300 A3 WO 0116300A3
Authority
WO
WIPO (PCT)
Prior art keywords
cdc25
catalytic domain
identifying inhibitors
polypeptides
dimensional structure
Prior art date
Application number
PCT/US2000/023473
Other languages
French (fr)
Other versions
WO2001016300A2 (en
Inventor
Neil R Taylor
David Borhani
David Epstein
Johannes Rudolph
Kurt Ritter
Taro Fujimori
Simon Robinson
Jens Eckstein
Andreas Haupt
Nigel Walker
Richard W Dixon
Deborah Choquette
Jill Blanchard
Arthur Kluge
Kollol Pal
Nicholas Bockovich
Jon Come
Mark Hediger
Original Assignee
Basf Ag
Gpc Biotech Inc
Neil R Taylor
David Borhani
David Epstein
Johannes Rudolph
Kurt Ritter
Taro Fujimori
Simon Robinson
Jens Eckstein
Andreas Haupt
Nigel Walker
Richard W Dixon
Deborah Choquette
Jill Blanchard
Arthur Kluge
Kollol Pal
Nicholas Bockovich
Jon Come
Mark Hediger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag, Gpc Biotech Inc, Neil R Taylor, David Borhani, David Epstein, Johannes Rudolph, Kurt Ritter, Taro Fujimori, Simon Robinson, Jens Eckstein, Andreas Haupt, Nigel Walker, Richard W Dixon, Deborah Choquette, Jill Blanchard, Arthur Kluge, Kollol Pal, Nicholas Bockovich, Jon Come, Mark Hediger filed Critical Basf Ag
Priority to EP00959449A priority Critical patent/EP1226237A2/en
Priority to JP2001520848A priority patent/JP2003508049A/en
Priority to AU70774/00A priority patent/AU7077400A/en
Priority to CA002383603A priority patent/CA2383603A1/en
Publication of WO2001016300A2 publication Critical patent/WO2001016300A2/en
Publication of WO2001016300A3 publication Critical patent/WO2001016300A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1027—Tetrapeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention relates to polypeptides which comprise the ligand binding domain of Cdc25, crystalline forms of these polypeptides and the use of these crystalline forms to determine the three dimensional structure of the catalytic domain of Cdc25. The invention also relates to the use of the three dimensional structure of the Cdc25 catalytic domain in methods of designing and/or identifying potential inhibitors of Cdc25 activity, for example, compounds which inhibit the binding of a native substrate to the Cdc25 catalytic domain.
PCT/US2000/023473 1999-08-31 2000-08-25 Method of identifying inhibitors of cdc25 WO2001016300A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00959449A EP1226237A2 (en) 1999-08-31 2000-08-25 Method of identifying inhibitors of cdc25
JP2001520848A JP2003508049A (en) 1999-08-31 2000-08-25 Methods for identifying inhibitors of Cdc25
AU70774/00A AU7077400A (en) 1999-08-31 2000-08-25 Method of identifying inhibitors of cdc25
CA002383603A CA2383603A1 (en) 1999-08-31 2000-08-25 Method of identifying inhibitors of cdc25

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17221599P 1999-08-31 1999-08-31
US60/172,215 1999-08-31

Publications (2)

Publication Number Publication Date
WO2001016300A2 WO2001016300A2 (en) 2001-03-08
WO2001016300A3 true WO2001016300A3 (en) 2002-05-30

Family

ID=22626790

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023473 WO2001016300A2 (en) 1999-08-31 2000-08-25 Method of identifying inhibitors of cdc25

Country Status (5)

Country Link
EP (1) EP1226237A2 (en)
JP (1) JP2003508049A (en)
AU (1) AU7077400A (en)
CA (1) CA2383603A1 (en)
WO (1) WO2001016300A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070680A1 (en) * 2001-03-01 2002-09-12 Basf Aktiengesellschaft Method of identifying inhibitors of cdc25
AU2003223602B8 (en) * 2002-04-11 2010-05-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease
US7057052B2 (en) 2002-09-26 2006-06-06 Duke University Heterocyclic quinones as pharmaceutical agents
UY28500A1 (en) 2003-09-05 2005-04-29 Vertex Pharma INHIBITORS OF SERINE PROTEASES, IN PARTICULAR PROTEASA NS3-NS4A HCV.
AR055361A1 (en) 2005-07-29 2007-08-22 Medivir Ab MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS
SI1913015T1 (en) 2005-07-29 2014-05-30 Janssen R&D Ireland Macrocyclic inhibitors of hepatitis c virus
CN101448512B (en) * 2005-12-14 2015-11-25 Ambrx公司 Purposes containing alpha-non-natural amino acid and the compositions of polypeptide, the method relating to alpha-non-natural amino acid and polypeptide and alpha-non-natural amino acid and polypeptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010242A1 (en) * 1991-11-18 1993-05-27 Cold Spring Harbor Laboratory NOVEL HUMAN cdc25 GENES, ENCODED PRODUCTS AND USES THEREFOR
US5925660A (en) * 1996-07-30 1999-07-20 University Of Pittsburgh Phosphatase inhibitors and methods of use thereof
WO2001027077A2 (en) * 1999-10-12 2001-04-19 Basf Aktiengesellschaft Hydroxysulfonylalkylene-, phosphonoalkylene- or difluoro(phosphononon)methyl- substituted benzene, or benzofuran derivatives as non-peptidic cdc25 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010242A1 (en) * 1991-11-18 1993-05-27 Cold Spring Harbor Laboratory NOVEL HUMAN cdc25 GENES, ENCODED PRODUCTS AND USES THEREFOR
US5925660A (en) * 1996-07-30 1999-07-20 University Of Pittsburgh Phosphatase inhibitors and methods of use thereof
WO2001027077A2 (en) * 1999-10-12 2001-04-19 Basf Aktiengesellschaft Hydroxysulfonylalkylene-, phosphonoalkylene- or difluoro(phosphononon)methyl- substituted benzene, or benzofuran derivatives as non-peptidic cdc25 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FAUMAN ERIC B ET AL: "Crystal structure of the catalytic domain of the human cell cycle control phosphatase, Cdc25A.", CELL, vol. 93, no. 4, 15 May 1998 (1998-05-15), pages 617 - 625, XP002181703, ISSN: 0092-8674 *
REYNOLDS ROSS A ET AL: "Crystal structure of the catalytic subunit of Cdc25B required for G2/M phase transition of the cell cycle.", JOURNAL OF MOLECULAR BIOLOGY, vol. 293, no. 3, 29 October 1999 (1999-10-29), pages 559 - 568, XP002181702, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
EP1226237A2 (en) 2002-07-31
JP2003508049A (en) 2003-03-04
CA2383603A1 (en) 2001-03-08
WO2001016300A2 (en) 2001-03-08
AU7077400A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
WO2003020880A3 (en) Method of identifying inhibitors of lck
AU6780300A (en) Automated analysis for financial assets
NO20015650L (en) Pyrrolotriazine Inhibitors for Kinases
ZA9811570B (en) SRC Family SH2 domain inhibitors.
DK125696A (en) Inhibitors for rotamase enzyme activity
ID20637A (en) METHODS FOR INHIBITING THE FORMATION OF BIOGENIC SULFIDA
EE200000522A (en) Phospholipase A2 Enzyme Inhibitor, a Pharmaceutical Composition Containing It and a Method for Inhibiting the Phospholipase Enzyme Activity
AU2001247984A1 (en) Workflow integration system for enterprise wide electronic collaboration
HK1026817A2 (en) Method for charting financial market activities
NO20004550D0 (en) Enzyme inhibitors
NO20006515D0 (en) Logging data dump probe
DE69905582T2 (en) Heterocyclic Compounds as Radamase Enzymes Inhibitors
EP1115389A4 (en) Fructosamine oxidase: antagonists and inhibitors
ZA200001333B (en) Method for communicating information.
NO20022742D0 (en) Telemetry system for borehole logs
EP1184665A4 (en) Method for measuring protein kinase activity
DE69906152D1 (en) 4-ALKENYL (AND ALKINYL) OXOINDOLE AS INHIBITORS CYCLINE-DEPENDENT KINASES, ESPECIALLY CDK2
MXPA01009915A (en) INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF.
DE60009888D1 (en) SUBSTITUTED 3-CYANO- [1.7], [1.5] AND [1.8] NAPHTHYRIDINE INHIBITORS OF TYROSIN KINASEN
EP1065213A3 (en) HCV polymerase suitable for crystal structure analysis and method for using the enzyme
PL355098A1 (en) Imidazole compounds used as phosphodiesterase vii inhibitors
WO2001072778A3 (en) Method of identifying inhibitors of tie-2
ZA985026B (en) Method for enhancing the activity of an enzyme.
WO2001016300A3 (en) Method of identifying inhibitors of cdc25
AU2003270037A1 (en) Methods for measuring kinase activity and phosphatase activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 70774/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2383603

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 520848

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000959449

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWP Wipo information: published in national office

Ref document number: 2000959449

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000959449

Country of ref document: EP